384 related articles for article (PubMed ID: 11982722)
21. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
Hasson H; Messina E; Merli M; Della Torre L; Morsica G; Bagaglio S; Lazzarin A; Uberti-Foppa C
Int J Infect Dis; 2014 Dec; 29():100-2. PubMed ID: 25449243
[TBL] [Abstract][Full Text] [Related]
22. Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
Christensen PB; Krarup HB; Laursen AL; Madsen PH; Pedersen C; Schlichting P; Orholm M; Ring-Larsen H; Bukh J; Krogsgaard K
Scand J Gastroenterol; 2012 Sep; 47(8-9):1115-9. PubMed ID: 22670704
[TBL] [Abstract][Full Text] [Related]
23. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
Formann E; Steindl-Munda P; Hofer H; Jessner W; Bergholz U; Gurguta C; Ferenci P
Aliment Pharmacol Ther; 2006 Feb; 23(4):507-11. PubMed ID: 16441471
[TBL] [Abstract][Full Text] [Related]
26. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
27. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
28. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
[TBL] [Abstract][Full Text] [Related]
29. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
31. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
32. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
33. [Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
Lee JE; Yoon NR; Kim JD; Song MJ; Kwon JH; Bae SH; Choi JY; Jeong SW; Yoon SK
Korean J Gastroenterol; 2011 Mar; 57(3):173-9. PubMed ID: 21519165
[TBL] [Abstract][Full Text] [Related]
34. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
[TBL] [Abstract][Full Text] [Related]
35. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
36. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
37. [Hepatitis C--treatment of untreated (naive) patients].
Duvnjak M; Pavić T; Tomasić V; Lerotić I; Virović L
Acta Med Croatica; 2005; 59(5):453-61. PubMed ID: 16381243
[TBL] [Abstract][Full Text] [Related]
38. Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Spelman T; Matthews G; Rice TM; Morris MD; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns MP; Hellard ME; Dore GJ;
J Viral Hepat; 2015 Dec; 22(12):1020-32. PubMed ID: 26098993
[TBL] [Abstract][Full Text] [Related]
39. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
[TBL] [Abstract][Full Text] [Related]
40. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies.
Fabrizi F; Dixit V; Messa P; Martin P
J Viral Hepat; 2014 Oct; 21(10):681-9. PubMed ID: 25040244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
